Tech Transfer eNews Blog

Biohaven and KU Leuven enter license agreement for novel pain treatment


By Jesse Schwartz
Published: January 11th, 2022

Biohaven Therapeutics and Katholieke Universiteit Leuven (KU Leuven) in Belgium have entered into an exclusive license agreement to advance a novel treatment for pain into the marketplace.

Developed by researchers at KU Leuven’s Centre for Drug Design and Discovery (CD3), BHV-2100 is a first-in-class TPRM3 antagonist addressing the growing number of people worldwide suffering from chronic pain disorders.

TRPM3 is a caption channel involved in pain signaling. BHV-2100 has demonstrated promising efficiency in targeting TRPM3 and reducing pain without the harmful side effects associated with other pain management approaches.

Under the agreement, the university will receive an upfront payment and is eligible to receive additional milestone payments. Biohaven will have exclusive global rights to develop, manufacture and commercialize the novel treatment as well as other TRPM3 antagonists developed at KU Leuven. The company will also support further basic research and translational research at KU Leuven on TRPM3 and its role in pain disorders.

“Biohaven has a proven track record of successfully developing and launching novel therapies,” says Patrick Chatlin, managing director of CD3. “We’re excited to work with Biohaven through this global license and research collaboration agreement.”

Source: Cision

Posted under: Tech Transfer e-News